Valeant Appoints EVP, CFO

Robert L. Rosiello has been appointed executive vice president, Valeant Pharmaceuticals, and will take over the role of chief financial officer effective July 1. He succeeds Howard Schiller as CFO, who will remain on Valeant’s Board and serve as a consultant.
 
Mr. Rosiello spent 30 years with McKinsey & Company working with healthcare, technology and consumer companies to deliver growth through M&A and financial performance improvement. As Senior Partner in charge of the global merger practice for the past decade, Mr. Rosiello led M&A integrations for pharmaceutical, specialty pharmaceutical and medical device companies in the U.S., Europe and Asia.
 
“The Board and I are delighted that Rob has agreed to join Valeant,” said J. Michael Pearson, chairman and chief executive officer. “Rob is someone I have worked closely with for 20 years. I know his tremendous expertise in healthcare and in particular M&A, his unquestioned intellect, and work ethic and integrity will prove to be of great value to the Valeant organization and its shareholders. I want to thank Howard for his strong leadership to both myself and the entire organization these past few years and I will continue to rely on his valuable counsel as a member of our Board of Directors.”